Trials in Long Beach, California
Here are the top 10 medical studies for breast cancer in Long Beach, California
Popular Filters
Phase 3 Trials
Selective Estrogen Receptor Degrader (SERD)
Camizestrant for Early Breast Cancer
Recruiting2 awardsPhase 3
Los Alamitos, California
This trial is testing camizestrant, a drug that blocks estrogen, in patients with ER+/HER2- early breast cancer at medium to high risk of recurrence. The goal is to see if it works better than standard hormone treatments by stopping cancer cells from growing.
Monoclonal Antibodies
Atezolizumab + Standard Therapy for HER2-Positive Breast Cancer
Recruiting1 awardPhase 3
Harbor City, California
This trial is studying how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic).
Chemotherapy
Chemotherapy + HER2-Targeted Therapy With or Without Hormone Therapy for Breast Cancer
Recruiting4 awardsPhase 3
Harbor City, California
This trial is studying a combination of drugs given with or without hormone therapy to see how well they work in treating patients with hormone receptor-positive, HER2-positive breast cancer.
Trials With No Placebo
Selective Estrogen Receptor Degrader (SERD)
Camizestrant for Early Breast Cancer
Recruiting2 awardsPhase 3
Los Alamitos, California
This trial is testing camizestrant, a drug that blocks estrogen, in patients with ER+/HER2- early breast cancer at medium to high risk of recurrence. The goal is to see if it works better than standard hormone treatments by stopping cancer cells from growing.
Chemotherapy
PF-07220060 + PF-07104091 for Breast Cancer
Recruiting1 awardPhase 1 & 2
Santa Monica, California
This trial tests two new oral medicines, PF-07220060 and PF-07104091, in people with different types of breast cancer. It aims to find the safest and most effective dose by gradually increasing the amount given to participants. The study will last several years, during which participants will be monitored for safety and treatment effects.
PD-L1 Inhibitor
SGN-PDL1V for Cancer
Recruiting1 awardPhase 1
Orange, California
This trial is testing a new drug, SGN-PDL1V, alone and with pembrolizumab, in patients with advanced solid tumors. The goal is to see if these treatments are safe and effective. SGN-PDL1V targets cancer cells directly, while pembrolizumab helps the immune system fight the cancer.
Monoclonal Antibodies
ARX788 for HER2-Positive Breast Cancer
Recruiting1 awardPhase 2
Torrance, California
This trial tests ARX788, a new IV medicine, for patients with HER2-positive metastatic breast cancer who did not respond well to T-DXd. The medicine targets a specific protein on cancer cells to help stop their growth.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.